Correlation Between Lumos Pharma and Exicure

Can any of the company-specific risk be diversified away by investing in both Lumos Pharma and Exicure at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lumos Pharma and Exicure into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Lumos Pharma and Exicure, you can compare the effects of market volatilities on Lumos Pharma and Exicure and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lumos Pharma with a short position of Exicure. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lumos Pharma and Exicure.

Diversification Opportunities for Lumos Pharma and Exicure

0.0

Correlation Coefficient

Lumos Pharma  Exicure

Pay attention - limited upside

The 3 months correlation between Lumos and Exicure is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Lumos Pharma and Exicure in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Exicure and Lumos Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lumos Pharma are associated (or correlated) with Exicure. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Exicure has no effect on the direction of Lumos Pharma i.e., Lumos Pharma and Exicure go up and down completely randomly.

Pair Corralation between Lumos Pharma and Exicure

If you would invest  1,615  in Exicure on December 29, 2024 and sell it today you would lose (215.00) from holding Exicure or give up 13.31% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Flat
Strength	Insignificant
Accuracy	0.0%
Values	Daily Returns

Lumos Pharma  vs.  Exicure

Lumos Pharma

Risk-Adjusted Performance

Very Weak

Over the last 90 days Lumos Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy primary indicators, Lumos Pharma is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors.

Exicure

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Exicure are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Exicure reported solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Lumos Pharma and Exicure

The main advantage of trading using opposite Lumos Pharma and Exicure positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lumos Pharma position performs unexpectedly, Exicure can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Exicure will offset losses from the drop in Exicure's long position.

The idea behind Lumos Pharma and Exicure pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.